EUCTR2014-004197-42-DE进行中（未招募）1 期
A proof of concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 Treatment Protocol) for recurrent glioblastoma - CUSP9v3
niversity Hospital of Ulm0 个研究点目标入组 10 人开始时间: 2016年3月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients with a diagnosis of glioblastoma WHO grade IV (histologically confirmed by a pathologist). Patients with prior low-grade glioma are eligible if histological transformation to WHO grade IV glioblastoma was confirmed.
- •2.Progression (according to RANO criteria) after prior radiation and temozolomide treatment
- •3.No more than 3 prior episodes of tumor progression
- •4.= 4 weeks between surgical resection or chemotherapy
- •5.= 12 weeks since last radiotherapy
- •6.Patients > 18 years of age.
- •7.Karnofsky performance status (KPS) of = 70%
- •8.Stable steroid dose for = 1 week
- •9.QT interval < 410 ms on ECG
- •10.Haematocrit >29%
- •11.ANC >10³ cells/µl
- •12.Platelet count >105/µl
- •13.Maximum 5 years since last Pneumovax (or equivalent) and varicella vaccination
- •14.Serum creatinine, AST and bilirubin = 1.5 times the IULN
- •15.Female patients of childbearing potential with a negative pregnancy test within 7 days of initiation of study treatment. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
- •16.Male and female patients of reproductive potential who agree to employ an effective method of birth control throughout the study and for up to 6 months following discontinuation of study drug.*
- •17.Signed informed consent prior to initiation of any study procedure (Must understand, voluntarily sign the informed consent form and be able to adhere to the study visit schedule and other protocol requirements.)
- •* s. Appendix II – Pregnancy Prevention Risk Management Plan
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 5
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1.Female patients who are pregnant or breast-feeding
- •2.Any uncontrolled/unstable medical condition except glioblastoma, including but not limited to uncontrolled/unstable hypertension, uncontrolled/unstable diabetes, uncontrolled endocrinopathies of any kind, uncontrolled/unstable psychiatric conditions
- •3.Renal failure (eGFR <60 ml/min)
- •4.Active infection
- •5.Therapeutic anticoagulation use
- •6.Prior stereotactic radiosurgery
- •7.Radiation implants
- •8.Radiolabeled monoclonal antibody therapy unless there was unequivocal disease progression (e.g. a new lesion or biopsy confirmed recurrence)
- •9.History of severe hypersensitivity reaction (=grade 3) to any component of the investigational drugs or excipients
- •10.Unable to undergo contrast-enhanced MRI
- •11.Patients who have been treated with any investigational agent(s) within 28 days of the first day of administration of study drugs.
- •12.Current active second malignancy other than non-melanoma skin cancers and post-treatment of localized prostate cancer. Patients are not considered to have a currently active malignancy if they are in complete remission for > 3 years prior to study
- •13.Known HIV infection, active Hepatitis B or C infection
- •14.Any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity (except alopecia) and delayed recovery following last temozolomide cycle
- •15.Additional anti-cancer treatment for glioblastoma other than study drug and supportive measures (i.e. dexamethasone)
研究者
相似试验
已完成
1 期
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent GlioblastomaC71GlioblastomaMalignant neoplasm of brainDRKS00022861niversitätsklinikum Ulm, Kliniken am oberen Eselsberg10
已完成
不适用
Allogeneic NK Cell (SMT-NK) in Combination With Pembrolizumab in Advanced Biliary Tract CancerKCT0004324SMT Bio40
已完成
不适用
Safety of the Pronokal method in obese diabetic patients: The Diaprokal study.ISRCTN55835754Pronokal® Group90
已完成
2 期
effect of Sovodak in patients with hepatitis C and HIV-1Condition 1: Hepatitis C and HIV. Condition 2: Human immunodeficiency virus.Acute hepatitis CHuman immunodeficiency virus [HIV] diseaseIRCT20180924041107N1Tabriz University of Medical Sciences22
已完成
1 期
A proof-of-concept clinical trial to evaluate the efficacy and safety of combined use of cefadroxil and tyrosine kinase inhibitors in minimal residual disease-positive patients with chronic phase chronic myelogenous leukemiaChronic myelogenous leukemiaJPRN-UMIN000027904Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University.